Parkinson's Disease/Movement Disorders News

Aptinyx Inc. announced it has completed enrollment in the company’s ongoing phase 2 study of NYX-458, an oral treatment for cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

An at-home, artificial intelligence-based system identified individuals with Parkinson’s disease and predicted disease severity and progression using nocturnal breathing signals, according to a study in Nature Medicine.

Healthy dietary habits and an active lifestyle were associated with a lower rate of all-cause mortality in adults with Parkinson’s disease, according to a study published in JAMA Network Open.

The Cleveland Clinic has developed an immersive virtual reality experience that combines traditional VR software with an omnidirectional treadmill to treat freezing of gait, which can accompany Parkinson’s disease.

The Michael J. Fox Foundation for Parkinson’s Research has awarded a research grant to health care technology company Koneksa to evaluate Parkinson’s disease progression using digital measures.

A flexible, implantable electronic device may have clinical application in the treatment of spinal cord injuries and Parkinson’s disease, researchers reported in Proceedings of the National Academy of Sciences.

The Parkinson’s Foundation has announced $1.1 million in funding for the Institutional Movement Disorder Fellowship Program and the Nurse Practitioner Fellowship in Movement Disorders.

Tinnitus affects more than 740 million adults worldwide and is viewed as a major problem by over 120 million, highlighting the need for improved research and patient care, according to a systematic review in JAMA Neurology.

The Parkinson’s Foundation has announced the expansion of its global care network with the addition of four Centers of Excellence and six Comprehensive Care Centers to increase access to high-quality care throughout the United States.

Continuous subcutaneous infusion of foslevodopa/foscarbidopa was safe and improved motor complications in patients with advanced Parkinson’s disease, according to data presented at the European Academy of Neurology Congress 2022.